Discovery of cancer common and specific driver gene sets
暂无分享,去创建一个
[1] C. Yeang,et al. Combinatorial patterns of somatic gene mutations in cancer , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[2] Christoph Schmid,et al. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia , 2016, Haematologica.
[3] Muhammad Mustafa,et al. CTCF negatively regulates HOXA10 expression in breast cancer cells. , 2015, Biochemical and biophysical research communications.
[4] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[5] Shihua Zhang,et al. Toward a systematic understanding of cancers: a survey of the pan-cancer study , 2014, Front. Genet..
[6] Marcel J. T. Reinders,et al. Identification of Networks of Co-Occurring, Tumor-Related DNA Copy Number Changes Using a Genome-Wide Scoring Approach , 2010, PLoS Comput. Biol..
[7] Giovanni Parmigiani,et al. Patient-oriented gene set analysis for cancer mutation data , 2010, Genome Biology.
[8] Daniel J Weisdorf,et al. Acute Myeloid Leukemia. , 2015, The New England journal of medicine.
[9] Adam J Mead,et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. , 2008, Blood.
[10] Caroline Dive,et al. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer , 2010, Cancer biology & therapy.
[11] Benjamin J. Raphael,et al. Pan-Cancer Network Analysis Identifies Combinations of Rare Somatic Mutations across Pathways and Protein Complexes , 2014, Nature Genetics.
[12] M. Roizen,et al. Hallmarks of Cancer: The Next Generation , 2012 .
[13] Shivendra V. Singh,et al. Notch2 activation is protective against anticancer effects of zerumbone in human breast cancer cells , 2014, Breast Cancer Research and Treatment.
[14] G. Parmigiani,et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.
[15] Simo V. Zhang,et al. A map of human cancer signaling , 2007, Molecular systems biology.
[16] Y. Kim,et al. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma , 2010, BMC Cancer.
[17] K. Sandvig,et al. Regulation of ErbB2 localization and function in breast cancer cells by ERM proteins , 2016, Oncotarget.
[18] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[19] Shihua Zhang,et al. Tumor characterization and stratification by integrated molecular profiles reveals essential pan-cancer features , 2015, BMC Genomics.
[20] Henry W. Long,et al. Somatic Cell Fusions Reveal Extensive Heterogeneity in Basal-like Breast Cancer. , 2015, Cell reports.
[21] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[22] Shi-Hua Zhang,et al. Efficient methods for identifying mutated driver pathways in cancer , 2012, Bioinform..
[23] M. Hottiger,et al. Transcription coactivator p300 binds PCNA and may have a role in DNA repair synthesis , 2001, Nature.
[24] J. Kostic,et al. Parallel targeted next generation sequencing of childhood and adult acute myeloid leukemia patients reveals uniform genomic profile of the disease , 2016, Tumor Biology.
[25] Niko Beerenwinkel,et al. Modeling Mutual Exclusivity of Cancer Mutations , 2014, RECOMB.
[26] É. Remy,et al. A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis. , 2015, Cancer research.
[27] K. Tewari,et al. A review of HER2-targeted therapy in breast and ovarian cancer: lessons from antiquity - CLEOPATRA and PENELOPE. , 2015, Future oncology.
[28] Andrew M. Gross,et al. Network-based stratification of tumor mutations , 2013, Nature Methods.
[29] P. Laird,et al. Discovery of multi-dimensional modules by integrative analysis of cancer genomic data , 2012, Nucleic acids research.
[30] Shi-Hua Zhang,et al. Discovery of co-occurring driver pathways in cancer , 2014, BMC Bioinformatics.
[31] Chris Sander,et al. Emerging landscape of oncogenic signatures across human cancers , 2013, Nature Genetics.
[32] Teresa M. Przytycka,et al. MEMCover: integrated analysis of mutual exclusivity and functional network reveals dysregulated pathways across multiple cancer types , 2015, Bioinform..
[33] B. Ponder,et al. FGFR2 risk SNPs confer breast cancer risk by augmenting oestrogen responsiveness , 2016, Carcinogenesis.
[34] Yan Zhang,et al. Comparative serum proteome analysis of human lymph node negative/positive invasive ductal carcinoma of the breast and benign breast disease controls via label-free semiquantitative shotgun technology. , 2009, Omics : a journal of integrative biology.
[35] A. Cimino-Mathews,et al. The role of GATA3 in breast carcinomas: a review. , 2016, Human pathology.
[36] P. Ding,et al. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review , 2015, Drug design, development and therapy.
[37] K. Kinzler,et al. Cancer genes and the pathways they control , 2004, Nature Medicine.
[38] Benjamin J. Raphael,et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.
[39] Ki-Chun Yoo,et al. Radiation driven epithelial-mesenchymal transition is mediated by Notch signaling in breast cancer , 2016, Oncotarget.
[40] Gary D Bader,et al. International network of cancer genome projects , 2010, Nature.
[41] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[42] H. Cai,et al. Roles of LPA receptor signaling in breast cancer , 2016, Expert review of molecular diagnostics.
[43] C. Sander,et al. Mutual exclusivity analysis identifies oncogenic network modules. , 2012, Genome research.
[44] Roded Sharan,et al. Simultaneous Identification of Multiple Driver Pathways in Cancer , 2013, PLoS Comput. Biol..
[45] A. Ziogas,et al. Novel polymorphisms in caspase-8 are associated with breast cancer risk in the California Teachers Study , 2016, BMC Cancer.
[46] C. Cui,et al. GNAQ and GNA11 mutations occur in 9.5% of mucosal melanoma and are associated with poor prognosis. , 2016, European journal of cancer.
[47] P. Elizalde,et al. ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. , 2016, Endocrine-related cancer.
[48] E. Birney,et al. Patterns of somatic mutation in human cancer genomes , 2007, Nature.
[49] E. Lander,et al. Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.
[50] Junhua Zhang,et al. The Discovery of Mutated Driver Pathways in Cancer: Models and Algorithms , 2016, IEEE/ACM Transactions on Computational Biology and Bioinformatics.
[51] G. Hardiman,et al. Amplification of WHSC1L1 regulates expression and estrogen‐independent activation of ERα in SUM‐44 breast cancer cells and is associated with ERα over‐expression in breast cancer , 2016, Molecular oncology.
[52] Sharon I. Greenblum,et al. Detecting Cancer Gene Networks Characterized by Recurrent Genomic Alterations in a Population , 2011, PloS one.
[53] Adam A. Margolin,et al. Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity , 2018, Nature.
[54] Nicolò Riggi,et al. Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing. , 2016, American journal of human genetics.
[55] Christopher A. Miller,et al. Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors , 2011, BMC Medical Genomics.
[56] Brian H. Dunford-Shore,et al. Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.
[57] Tzu-Pin Lu,et al. Prognostic significance of NPM1 mutation-modulated microRNA−mRNA regulation in acute myeloid leukemia , 2016, Leukemia.
[58] Brad T. Sherman,et al. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources , 2008, Nature Protocols.
[59] Raul Rabadan,et al. An information theoretic method to identify combinations of genomic alterations that promote glioblastoma. , 2015, Journal of molecular cell biology.
[60] Eli Upfal,et al. De Novo Discovery of Mutated Driver Pathways in Cancer , 2011, RECOMB.
[61] M. Stratton,et al. The cancer genome , 2009, Nature.
[62] C. Annunziata,et al. Caspase 8 expression may determine the survival of women with ovarian cancer , 2016, Cell Death and Disease.
[63] Benjamin J. Raphael,et al. Mutational landscape and significance across 12 major cancer types , 2013, Nature.
[64] Y. Hamamoto,et al. Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma , 2009, Investigational new drugs.
[65] Shi-Hua Zhang,et al. Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data , 2013, BMC Systems Biology.
[66] W. Hogan,et al. Prognostic impact of combined NPM1+/FLT3- genotype in patients with acute myeloid leukemia with intermediate risk cytogenetics stratified by age and treatment modalities. , 2015, Leukemia research.
[67] J. Vince,et al. New insights into the regulation of innate immunity by caspase-8 , 2016, Arthritis Research & Therapy.
[68] B. Dołęgowska,et al. Lysophosphatidic acid signaling in ovarian cancer , 2015, Journal of receptor and signal transduction research.